Patients with diabetes mellitus (DM) causes progressive reduction of a diabetic retinopathy (DR). The characteristic symptoms are intraocular hemorrhage DR - hemophthalmus.
Depending on the amount of blood streamed there are three degrees of hemophthalmia: partial, subtotal and total, in which the vitreous body covered with blood, respectively, at 25.50 and more than 50%. Hemorrhage can be preretinal (retrogialoid), or a combination of intravitreal.
A well-known conservative treatment hemophthalmus in diabetic retinopathy is the enzyme treatment (most often gemaza, kollalizin, Vobenzim). To ensure adequate drug effect requires several months Vobenzim use in large doses daily. Kollalizin has some major drawbacks (irritant effect on the eye, and allergic reactions). The most prominent among them is rapidly irritate the eyewithin
5 – 7 days after administration of doses higher concentrations (800 – 900 KE), providing an effective impact on the process of resorption. A second drawback of the drug - an allergic reaction that can develop in the area of the eye, surrounding tissue and the skin of the face, even after an absence of any allergic reaction to a drug test. This side effect of the drug must be taken into account when considering its use in immunologically compromised patients, which include patients with diabetes. High thrombolytic and fibrinolytic activity, low toxicity and good tolerability has gemaza.
The literature contains information about using laser photocoagulation in combination with the resolution therapy gemaza hemophthalmus resorption in the presence of proliferative processes in the vitreous body and retina. This enables approximately 1.5-fold increase in the frequency of regression and stabilization of proliferative changes in the fundus, and significantly reduce the incidence of complications (36 %). At the same time significantly shortened treatment time, which improves the quality of life of patients with severe category on the background of improving visual function in the process of laser photocoagulation, and after it.